The test, which was developed by researchers at the Cleveland Clinic and the University of Alabama, looks for RNA molecules in urine that indicate rejection.
Last year, the company processed more than 1 million tests, most of them for its reproductive health business, but interest in Prospera and Signatera is growing.
CareDx expects fourth quarter revenues of $58.4 million to $58.6 million, an increase of approximately 63 percent compared to $35.8 million in Q4 2019.